Literature DB >> 22665562

Do not miss rifampicin-induced thrombocytopenic purpura.

Avinash Agrawal1, Manish Gutch, Nirdesh Jain, Ambukeshwar Singh.   

Abstract

Drug-induced immune thrombocytopenia (DITP) can be triggered by a wide range of medications. Although many cases of DITP are mild, some are characterised by life-threatening bleeding symptoms. In the treatment of tuberculosis there are special therapeutic problems related to adverse effects of drugs, compliance to treatment and microbial resistance. Thrombocytopenia is an uncommon but potentially fatal adverse effect of certain antituberculous drugs when the incriminating drug is taken by a susceptible individual. Here the authors report a case of rifampicin-induced thrombocytopenia, which although rare, needs attention.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22665562      PMCID: PMC3291025          DOI: 10.1136/bcr.12.2011.5282

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

1.  Antibodies against rifampin in patients with tuberculosis after discontinuation of daily treatment.

Authors:  L Di Berardino; G Perna; L G Silvestri
Journal:  Am Rev Respir Dis       Date:  1976-12

Review 2.  Treatment of drug-related diseases by plasma exchanges.

Authors:  O Pourrat
Journal:  Ann Med Interne (Paris)       Date:  1994

3.  Potentially serious side effects of high-dose twice-weekly rifampicin.

Authors:  G Poole; P Stradling; S Worlledge
Journal:  Br Med J       Date:  1971-08-07

4.  Drug-induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy.

Authors:  U Pedersen-Bjergaard; M Andersen; P B Hansen
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

5.  Intravenous immune globulin for the treatment of presumed quinidine-induced thrombocytopenia.

Authors:  J B Ray; W F Brereton; F R Nullet
Journal:  DICP       Date:  1990 Jul-Aug

6.  Editorial: Wet purpura, dry purpura.

Authors:  W H Crosby
Journal:  JAMA       Date:  1975-05-19       Impact factor: 56.272

7.  A controlled trial of daily and intermittent rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis: results up to 30 months.

Authors: 
Journal:  Tubercle       Date:  1975-09
  7 in total
  3 in total

1.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

2.  Authors' reply.

Authors:  Ramakant Dixit; Jacob George; Arun K Sharma
Journal:  Lung India       Date:  2012-10

3.  Case Report: Rifampicin-Induced Thrombocytopenia in a Patient with Borderline Lepromatous Leprosy.

Authors:  Tiejun Shui; Chao Shi; Zhichun Jing; Degang Yang; Jianyu Zhu
Journal:  Am J Trop Med Hyg       Date:  2020-10       Impact factor: 3.707

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.